In response to mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study.
E A
EA
Egan
D001688:Biological Products / Q000627:therapeutic use; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007902:Length of Stay; D008297:Male; D010743:Phospholipids / Q000627:therapeutic use; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012127:Respiratory Distress Syndrome, Newborn / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D016019:Survival Analysis
D001688:Biological Products; D010743:Phospholipids; D011663:Pulmonary Surfactants; C068291:poractant alfa; C117342:calfactant; C072197:beractant